Amantadine Effect on Perceptions of Irritability after Traumatic Brain Injury: Results of the Amantadine Irritability Multisite Study

Amantadine Irritability Multisite Study Group

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

This study examines the effect of amantadine on irritability in persons in the post-acute period after traumatic brain injury (TBI). There were 168 persons ≥ 6 months post-TBI with irritability who were enrolled in a parallel-group, randomized, double-blind, placebo-controlled trial receiving either amantadine 100 mg twice daily or equivalent placebo for 60 days. Subjects were assessed at baseline and days 28 (primary end-point) and 60 of treatment using observer-rated and participant-rated Neuropsychiatric Inventory (NPI-I) Most Problematic item (primary outcome), NPI Most Aberrant item, and NPI-I Distress Scores, as well as physician-rated Clinical Global Impressions (CGI) scale. Observer ratings between the two groups were not statistically significantly different at day 28 or 60; however, observers rated the majority in both groups as having improved at both intervals. Participant ratings for day 60 demonstrated improvements in both groups with greater improvement in the amantadine group on NPI-I Most Problematic (p < 0.04) and NPI-I Distress (p < 0.04). These results were not significant with correction for multiple comparisons. CGI demonstrated greater improvement for amantadine than the placebo group (p < 0.04). Adverse event occurrence did not differ between the two groups. While observers in both groups reported large improvements, significant group differences were not found for the primary outcome (observer ratings) at either day 28 or 60. This large placebo or nonspecific effect may have masked detection of a treatment effect. The result of this study of amantadine 100 mg every morning and noon to reduce irritability was not positive from the observer perspective, although there are indications of improvement at day 60 from the perspective of persons with TBI and clinicians that may warrant further investigation.

Original languageEnglish (US)
Pages (from-to)1230-1238
Number of pages9
JournalJournal of Neurotrauma
Volume32
Issue number16
DOIs
StatePublished - Aug 15 2015

Fingerprint

Amantadine
Placebos
Equipment and Supplies
Traumatic Brain Injury
Physicians
Therapeutics

Keywords

  • aggression
  • agitation
  • amantadine
  • brain injuries
  • irritability

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Amantadine Effect on Perceptions of Irritability after Traumatic Brain Injury : Results of the Amantadine Irritability Multisite Study. / Amantadine Irritability Multisite Study Group.

In: Journal of Neurotrauma, Vol. 32, No. 16, 15.08.2015, p. 1230-1238.

Research output: Contribution to journalArticle

@article{49c2a8031ef44eb881bb44ea41815c89,
title = "Amantadine Effect on Perceptions of Irritability after Traumatic Brain Injury: Results of the Amantadine Irritability Multisite Study",
abstract = "This study examines the effect of amantadine on irritability in persons in the post-acute period after traumatic brain injury (TBI). There were 168 persons ≥ 6 months post-TBI with irritability who were enrolled in a parallel-group, randomized, double-blind, placebo-controlled trial receiving either amantadine 100 mg twice daily or equivalent placebo for 60 days. Subjects were assessed at baseline and days 28 (primary end-point) and 60 of treatment using observer-rated and participant-rated Neuropsychiatric Inventory (NPI-I) Most Problematic item (primary outcome), NPI Most Aberrant item, and NPI-I Distress Scores, as well as physician-rated Clinical Global Impressions (CGI) scale. Observer ratings between the two groups were not statistically significantly different at day 28 or 60; however, observers rated the majority in both groups as having improved at both intervals. Participant ratings for day 60 demonstrated improvements in both groups with greater improvement in the amantadine group on NPI-I Most Problematic (p < 0.04) and NPI-I Distress (p < 0.04). These results were not significant with correction for multiple comparisons. CGI demonstrated greater improvement for amantadine than the placebo group (p < 0.04). Adverse event occurrence did not differ between the two groups. While observers in both groups reported large improvements, significant group differences were not found for the primary outcome (observer ratings) at either day 28 or 60. This large placebo or nonspecific effect may have masked detection of a treatment effect. The result of this study of amantadine 100 mg every morning and noon to reduce irritability was not positive from the observer perspective, although there are indications of improvement at day 60 from the perspective of persons with TBI and clinicians that may warrant further investigation.",
keywords = "aggression, agitation, amantadine, brain injuries, irritability",
author = "{Amantadine Irritability Multisite Study Group} and Hammond, {Flora M.} and Mark Sherer and Malec, {James F.} and Zafonte, {Ross D.} and Marybeth Whitney and Kathleen Bell and Sureyya Dikmen and Jennifer Bogner and Jerry Mysiw and Rashmi Pershad",
year = "2015",
month = "8",
day = "15",
doi = "10.1089/neu.2014.3803",
language = "English (US)",
volume = "32",
pages = "1230--1238",
journal = "Journal of Neurotrauma",
issn = "0897-7151",
publisher = "Mary Ann Liebert Inc.",
number = "16",

}

TY - JOUR

T1 - Amantadine Effect on Perceptions of Irritability after Traumatic Brain Injury

T2 - Results of the Amantadine Irritability Multisite Study

AU - Amantadine Irritability Multisite Study Group

AU - Hammond, Flora M.

AU - Sherer, Mark

AU - Malec, James F.

AU - Zafonte, Ross D.

AU - Whitney, Marybeth

AU - Bell, Kathleen

AU - Dikmen, Sureyya

AU - Bogner, Jennifer

AU - Mysiw, Jerry

AU - Pershad, Rashmi

PY - 2015/8/15

Y1 - 2015/8/15

N2 - This study examines the effect of amantadine on irritability in persons in the post-acute period after traumatic brain injury (TBI). There were 168 persons ≥ 6 months post-TBI with irritability who were enrolled in a parallel-group, randomized, double-blind, placebo-controlled trial receiving either amantadine 100 mg twice daily or equivalent placebo for 60 days. Subjects were assessed at baseline and days 28 (primary end-point) and 60 of treatment using observer-rated and participant-rated Neuropsychiatric Inventory (NPI-I) Most Problematic item (primary outcome), NPI Most Aberrant item, and NPI-I Distress Scores, as well as physician-rated Clinical Global Impressions (CGI) scale. Observer ratings between the two groups were not statistically significantly different at day 28 or 60; however, observers rated the majority in both groups as having improved at both intervals. Participant ratings for day 60 demonstrated improvements in both groups with greater improvement in the amantadine group on NPI-I Most Problematic (p < 0.04) and NPI-I Distress (p < 0.04). These results were not significant with correction for multiple comparisons. CGI demonstrated greater improvement for amantadine than the placebo group (p < 0.04). Adverse event occurrence did not differ between the two groups. While observers in both groups reported large improvements, significant group differences were not found for the primary outcome (observer ratings) at either day 28 or 60. This large placebo or nonspecific effect may have masked detection of a treatment effect. The result of this study of amantadine 100 mg every morning and noon to reduce irritability was not positive from the observer perspective, although there are indications of improvement at day 60 from the perspective of persons with TBI and clinicians that may warrant further investigation.

AB - This study examines the effect of amantadine on irritability in persons in the post-acute period after traumatic brain injury (TBI). There were 168 persons ≥ 6 months post-TBI with irritability who were enrolled in a parallel-group, randomized, double-blind, placebo-controlled trial receiving either amantadine 100 mg twice daily or equivalent placebo for 60 days. Subjects were assessed at baseline and days 28 (primary end-point) and 60 of treatment using observer-rated and participant-rated Neuropsychiatric Inventory (NPI-I) Most Problematic item (primary outcome), NPI Most Aberrant item, and NPI-I Distress Scores, as well as physician-rated Clinical Global Impressions (CGI) scale. Observer ratings between the two groups were not statistically significantly different at day 28 or 60; however, observers rated the majority in both groups as having improved at both intervals. Participant ratings for day 60 demonstrated improvements in both groups with greater improvement in the amantadine group on NPI-I Most Problematic (p < 0.04) and NPI-I Distress (p < 0.04). These results were not significant with correction for multiple comparisons. CGI demonstrated greater improvement for amantadine than the placebo group (p < 0.04). Adverse event occurrence did not differ between the two groups. While observers in both groups reported large improvements, significant group differences were not found for the primary outcome (observer ratings) at either day 28 or 60. This large placebo or nonspecific effect may have masked detection of a treatment effect. The result of this study of amantadine 100 mg every morning and noon to reduce irritability was not positive from the observer perspective, although there are indications of improvement at day 60 from the perspective of persons with TBI and clinicians that may warrant further investigation.

KW - aggression

KW - agitation

KW - amantadine

KW - brain injuries

KW - irritability

UR - http://www.scopus.com/inward/record.url?scp=84938319714&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938319714&partnerID=8YFLogxK

U2 - 10.1089/neu.2014.3803

DO - 10.1089/neu.2014.3803

M3 - Article

C2 - 25774566

AN - SCOPUS:84938319714

VL - 32

SP - 1230

EP - 1238

JO - Journal of Neurotrauma

JF - Journal of Neurotrauma

SN - 0897-7151

IS - 16

ER -